Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-IRDye800CW in Familial Adenomatous Polyposis
NCT02113202Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2014
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevacizumab-IRDye800CW in familial adenomatous polyposis (FAP) (3 arms), sponsored by University Medical Center Groningen. Primary endpoint: Number of fluorescent adenomatous polyps during surveillance endoscopy. Started Mar 2014; status: completed.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT02113202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113202.